Compare Ginkgo Bioworks Holdings Inc (DNA) vs Equinor ASA (EQNR) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

EQNR trades at $41.61, down 3.26% today, with a bearish technical outlook and mixed fundamental performance. The stock shows attractive valuation metrics including P/E of 11.63 and EV/EBITDA of 2.39, but faces declining profit margins from 19.29% in 2022 to 4.76% in 2025. Recent earnings show two beats and one miss, while analyst consensus remains positive with a $87.50 price target representing significant upside potential from current levels.

The investment case balances deep value characteristics against operational headwinds. While valuation appears compelling with strong cash flows and dividend payments, investors face risks from volatile energy markets and margin compression. The 112% upside to consensus target suggests Wall Street sees substantial recovery potential if operational performance improves.